---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-074989"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:57:08.363706+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Replimune reports Q1 FY2026 net loss $86.7M; FDA issues CRL for RP1 BLA

## Summary
- Net loss of $86.7M for quarter ended June 30, 2025, vs $53.8M a year ago.
- Cash, cash equivalents and short-term investments $403.3M; funding expected into Q4 2026.
- FDA issued Complete Response Letter for RP1 BLA in advanced melanoma on July 22, 2025.
- R&D expenses $57.8M (up from $43.0M); SG&A $32.6M (up from $14.4M), driven by commercial prep.
- Ongoing Phase 3 IGNYTE-3 trial for RP1+nivolumab; Phase 2/3 REVEAL trial for RP2 in uveal melanoma.

## SEC filing metadata
- accession: 0001104659-25-074989
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465925074989/0001104659-25-074989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465925074989/tm2522849d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-074989
- JSON: https://secwatch.observer/filing/0001104659-25-074989.json
- Plain text: https://secwatch.observer/filing/0001104659-25-074989.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.